![Figure 3 from Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. | Semantic Scholar Figure 3 from Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5b5fe1753c6637c3d8d05d3474c75480496dc8b7/7-Figure1-1.png)
Figure 3 from Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. | Semantic Scholar
![Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology](https://www.jrheum.org/content/jrheum/44/4/519/F2.large.jpg)
Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology
![PASI vs PO‐PASI: Patient‐Oriented PASI (PO‐PASI) is comparable to clinician score PASI - Montes de Oca Pedrosa - 2022 - Australasian Journal of Dermatology - Wiley Online Library PASI vs PO‐PASI: Patient‐Oriented PASI (PO‐PASI) is comparable to clinician score PASI - Montes de Oca Pedrosa - 2022 - Australasian Journal of Dermatology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/5e273e28-94f9-4a61-be41-3d02ba8af628/ajd13738-tbl-0001-m.jpg)
PASI vs PO‐PASI: Patient‐Oriented PASI (PO‐PASI) is comparable to clinician score PASI - Montes de Oca Pedrosa - 2022 - Australasian Journal of Dermatology - Wiley Online Library
![Comparison of efficacy, safety, and cost-effectiveness of topical salicylic acid 6% versus clobetasol propionate 0.05% in the treatment of limited chronic plaque psoriasis Comparison of efficacy, safety, and cost-effectiveness of topical salicylic acid 6% versus clobetasol propionate 0.05% in the treatment of limited chronic plaque psoriasis](https://www.jhrr.org/articles/2018/5/2/images/JHealthResRev_2018_5_2_86_238863_f1.jpg)
Comparison of efficacy, safety, and cost-effectiveness of topical salicylic acid 6% versus clobetasol propionate 0.05% in the treatment of limited chronic plaque psoriasis
![Table 3 from Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. | Semantic Scholar Table 3 from Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5b5fe1753c6637c3d8d05d3474c75480496dc8b7/8-Table3-1.png)
Table 3 from Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. | Semantic Scholar
![Psoriasis Area and Severity Index (PASI) score assessment (H, head; LL,... | Download Scientific Diagram Psoriasis Area and Severity Index (PASI) score assessment (H, head; LL,... | Download Scientific Diagram](https://www.researchgate.net/profile/Hugo-Oliveira-12/publication/221929000/figure/fig2/AS:304724734693382@1449663446939/Psoriasis-Area-and-Severity-Index-PASI-score-assessment-H-head-LL-lower-limbs-T_Q640.jpg)
Psoriasis Area and Severity Index (PASI) score assessment (H, head; LL,... | Download Scientific Diagram
![Psoriasis Area and Severity Index (PASI) score assessment (H, head; LL,... | Download Scientific Diagram Psoriasis Area and Severity Index (PASI) score assessment (H, head; LL,... | Download Scientific Diagram](https://www.researchgate.net/profile/Hugo-Oliveira-12/publication/221929000/figure/fig2/AS:304724734693382@1449663446939/Psoriasis-Area-and-Severity-Index-PASI-score-assessment-H-head-LL-lower-limbs-T_Q320.jpg)
Psoriasis Area and Severity Index (PASI) score assessment (H, head; LL,... | Download Scientific Diagram
![PASI and PQOL-12 score in psoriasis : Is there any correlation? Shankar V, Ghosh S, Ghosh K, Chaudhuri U - Indian J Dermatol PASI and PQOL-12 score in psoriasis : Is there any correlation? Shankar V, Ghosh S, Ghosh K, Chaudhuri U - Indian J Dermatol](https://e-ijd.org/articles/2011/56/3/images/IndianJDermatol_2011_56_3_287_82482_f2.jpg)